R
Ronald Goldenberg
Researcher at New York University
Publications - 103
Citations - 3899
Ronald Goldenberg is an academic researcher from New York University. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 24, co-authored 85 publications receiving 2763 citations. Previous affiliations of Ronald Goldenberg include University of Toronto & North York General Hospital.
Papers
More filters
Journal ArticleDOI
Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome.
Journal ArticleDOI
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma,C. David Mazer,C. David Mazer,Andrew T. Yan,Andrew T. Yan,Tamique Mason,Tamique Mason,Vinay Garg,Vinay Garg,Hwee Teoh,Fei Zuo,Adrian Quan,Michael E. Farkouh,Michael E. Farkouh,David Fitchett,David Fitchett,Shaun G. Goodman,Ronald Goldenberg,Mohammed Al-Omran,Mohammed Al-Omran,Richard E. Gilbert,Richard E. Gilbert,Deepak L. Bhatt,Lawrence A. Leiter,Lawrence A. Leiter,Peter Jüni,Peter Jüni,Bernard Zinman,Bernard Zinman,Kim A. Connelly +29 more
TL;DR: Among people with T2DM and CAD, SGLT2 inhibition with empagliflozin was associated with significant reduction in LVMi after 6 months, which may account in part for the beneficial cardiovascular outcomes observed in the EMPA-REG OUTCOME trial.
Journal ArticleDOI
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Thomas Forst,R. Guthrie,Ronald Goldenberg,Jacqueline Yee,Ujjwala Vijapurkar,Gary Meininger,Peter P. Stein +6 more
TL;DR: The efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus inadequately controlled with metformin and pioglitazone.
Journal ArticleDOI
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
C. David Mazer,Gregory M. T. Hare,Philip W. Connelly,Richard E. Gilbert,Nadine Shehata,Adrian Quan,Hwee Teoh,Lawrence A. Leiter,Bernard Zinman,Bernard Zinman,Peter Jüni,Fei Zuo,Nikhil Mistry,Kevin E. Thorpe,Kevin E. Thorpe,Ronald Goldenberg,Andrew T. Yan,Andrew T. Yan,Kim A. Connelly,Subodh Verma +19 more
TL;DR: The consistent observation of an increase in hematocrit, even in those without diabetes, has led to the hypothesis that SGLT2 inhibitors may increase erythropoiesis via enhanced eryanthropoietin (EPO) secretion by the kidney, which could lead to systemic organ protection.
Journal ArticleDOI
SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis
Ronald Goldenberg,Lori Berard,Alice Y.Y. Cheng,Jeremy Gilbert,Subodh Verma,Vincent Woo,Jean-François Yale +6 more
TL;DR: A cross-Canada expert panel and writing group were convened to review the evidence to-date on reported SGLT2 inhibitor-related diabetic ketoacidosis incidents and to offer recommendations for preventing and recognizing patients with S GLT2 inhibitors-associated DKA.